Skip to main content

Table 2 Comparison of clinical characteristics between group TMP and group TMN during the first visit

From: Clinical findings of Talaromyces marneffei infection among patients with anti-interferon-γ immunodeficiency: a prospective cohort study

Variable Group TMP (N = 22) Group TMN (N = 20) P value
Age, years 52.0 (34.8, 58.0) 54.5 (29.0, 63.8) 0.734
Male sex, no. (%) 14 (63.6%) 13 (65.0%) 1.0
Anti-IFN-γ antibody titer (ng/ml) 926.31 (760.02, 2103.20) 332.40 (243.51,491.89) <0.001
Time from symptom onset to diagnosis 149.5 (57.2, 272.3) 98.5 (22.3154.5) 0.107
Coexisting respiratory disease, no. (%) 3 (13.6%) 10 (50.0%) 0.019
 Bronchiolitis 0 4 (20.0%) 0.043
 COPD 2 (9.1%) 4 (20.0%) 0.400
 COPD with bronchiectasis 0 2 (10.0%) 0.221
 Asthma 1 (4.5%) 0 0.476
Extrapulmonary organ involvement, no. (%) 18 (81.8%) 11 (55.0%) 0.096
 Skin 10 (45.5%) 3 (15.0%) 0.047
 Lymph node 18 (81.8%) 11 (55.0%) 0.096
 Liver 2 (9.1%) 1 (5.0%) 1.000
 Spleen 2 (9.1%) 0 0.489
 Bone 9 (40.9%) 1 (5.0%) 0.010
Symptoms, no. (%)
 Fever 12 (54.5%) 6 (30.0%) 0.131
 Cough 17 (77.3%) 17 (85.0%) 0.700
 Sputum production 14 (63.6%) 15 (75.0%) 0.514
 Hemoptysis 4 (18.2%) 3 (15.0%) 1.0
 Dyspnea 6 (27.3%) 3 (15%) 0.460
 Chest pain 9 (40.9%) 6 (30.0%) 0.531
 Osteodynia/Arthralgia 7 (31.8%) 3 (15.0%) 0.284
 Wasting 13 (59.0%) 10 (50.0%) 0.757
 Moist rales 6 (27.3%) 8 (40.0%) 0.515
 Pleural effusion 13 (59.1%) 3 (15.0%) 0.005
 Co-infection, no. (%) 12 (55.0%) 4 (20.0%) 0.029
Outcome, no. (%)a
 Cured 0 2 (10.0%)
 Improved 2 (9.1%) 4 (20.0%)
 Ineffective 6 (27.3%) 0
 Recurrence 1 (4.5%) 0
 Death 3 (13.6%) 0
  1. aData were available for 12 patients in group TMP and 6 patients in group TMN during the longitudinal follow-up
  2. Group TMP = anti-IFN-γ autoantibody-positive group
  3. Group TMN = anti-IFN-γ autoantibody-negative group
  4. COPD Chronic obstructive pulmonary disease
  5. NTM Nontuberculous Mycobacterium